Neuronetics Stock Price, News & Analysis

Neuronetics (NASDAQ: STIM) announced inducement awards for new non-executive employee Jeff Jones, approved under NASDAQ Listing Rule 5635(c)(4). The compensation package includes 30,000 Performance Restricted Stock Units (PRSUs) tied to achieving cash flow breakeven in Q3 and Q4 2025, 27,500 PRSUs vesting in three installments through 2027 based on cash balance targets, and 112,500 Restricted Stock Units (RSUs) vesting equally over three years. The awards, granted under the Company's 2020 Inducement Incentive Plan, are contingent on continued employment through applicable vesting dates.

Neuronetics (NASDAQ: STIM) announced its participation as a Silver Sponsor at the 13th Annual Clinical TMS Society Meeting in San Diego from June 11-14, 2025. The company will present two significant posters using data from TrakStar, the largest real-world TMS outcomes database. The first presentation by Dr. Eleanor Cole focuses on TMS effectiveness in elderly adults with Major Depressive Disorder, while the second by Cory Anderson compares clinical outcomes between NeuroStar's Figure-8 coil and Brainsway's H-coil across 200 Greenbrook centers. Additionally, Greenbrook Mental Wellness Centers, a Neuronetics subsidiary, has launched a program evaluating personalized qEEG-informed protocols for TMS therapy using the NeuroStar system, with promising initial feasibility results.

Neuronetics (NASDAQ: STIM) announced its upcoming inclusion in both the Russell 2000® and Russell 3000® Indexes, effective June 30, 2025, following the annual reconstitution of Russell indexes. The Russell 3000® Index comprises the 3,000 largest U.S. public companies by market cap, while the Russell 2000® focuses on small-cap companies. These indexes, managed by FTSE Russell, serve as benchmarks for approximately $10.6 trillion in assets. CEO Keith J. Sullivan highlighted this inclusion as validation of their strategic vision in mental healthcare delivery, noting the company's expansion through NeuroStar technology and Greenbrook clinic network. The company expects to achieve positive cash flow in 2025 while maintaining strong growth through their operating model.

Neuronetics (NASDAQ: STIM) has launched the first National TMS Therapy Awareness Day, scheduled annually for May 14 during Mental Health Awareness Month. The initiative aims to raise awareness about transcranial magnetic stimulation (TMS) as a non-drug treatment option for major depressive disorder (MDD), depression with anxiety, and OCD. NeuroStar, the leading TMS therapy in the US, received FDA clearance for adolescent treatment in 2024, expanding its reach beyond adult patients. The treatment is covered by insurance plans for over 300 million people, including Medicare and Tricare. The company will showcase patient stories, including that of Kristen Gingrich, a licensed clinical social worker who found relief through NeuroStar TMS after struggling with depression. Additionally, NeuroStar will present research data at the 2025 American Psychiatric Association Annual Meeting, focusing on TMS protocols and treatment efficacy.

Neuronetics (NASDAQ: STIM) reported strong Q1 2025 financial results with revenue of $32.0 million, up 84% year-over-year, primarily driven by the Greenbrook acquisition. Key highlights include:

- U.S. clinic revenue: $18.7M (Greenbrook) - Treatment session revenue: $9.6M - NeuroStar System revenue: $2.8M

The company completed an $18.9M secondary offering in February 2025. Notable developments include CFO Steve Furlong's planned retirement in March 2026, major insurance coverage expansions for adolescent TMS treatment, and achieving over 202,000 global patients treated. Despite a Q1 net loss of $(12.7M), Neuronetics projects becoming cash flow positive in Q3 2025.

For 2025, Neuronetics updated guidance to $149.0M-$155.0M in total revenue, with Q2 2025 expected revenue between $36.0M-$38.0M. The company anticipates year-end cash above $20.0M.

Neuronetics (NASDAQ: STIM), a medical technology company specializing in neurohealth disorders, has granted Restricted Stock Units (RSUs) representing 4,500 shares of common stock to three new non-executive employees. The RSUs were approved by the company's Compensation Committee as inducement awards under NASDAQ Listing Rule 5635(c)(4). The RSUs will vest in equal installments over three years on the first, second, and third anniversaries of the grant date, contingent on continued employment. These awards fall under the Neuronetics 2020 Inducement Plan.

Neuronetics (NASDAQ: STIM), a medical technology company specializing in neurohealth disorders treatment solutions, has announced its upcoming first quarter 2025 financial results release. The company will disclose its Q1 2025 financial and operating results before the market opens on Tuesday, May 6, 2025.

A conference call to discuss the results is scheduled for 8:30 a.m. Eastern Time on the same day. Interested parties can access the live broadcast in listen-only mode via webcast, with telephone participants encouraged to register and join 10 minutes before the event start.

Neuronetics (NASDAQ: STIM) announced that Evernorth Health Services, a Cigna subsidiary, has expanded coverage of NeuroStar® Transcranial Magnetic Stimulation (TMS) to include adolescents aged 15 and older with major depressive disorder (MDD). This expansion, effective immediately, impacts 15 million covered lives.

The coverage update follows NeuroStar's FDA clearance as the first first-line add-on treatment for adolescents aged 15-21 with MDD. Several major insurers, including Humana, Aetna, and Medi-Cal, have updated their policies in response to this clearance.

The expansion addresses a significant need, as approximately 4.3 million U.S. adolescents aged 15-21 are affected by major depression. NeuroStar TMS offers a non-drug treatment option that can be used as a first-line add-on therapy with proven clinical outcomes.

Neuronetics (NASDAQ: STIM) has issued updated financial results for Q4 and full year 2024, revising figures initially reported on March 4, 2025. The revisions, related to the Greenbrook TMS acquisition, include:

For Q4 2024: Operating expenses increased to $26.4M from $25.8M, net loss widened to $(12.7M) from $(12.2M), loss per share increased to $(0.34) from $(0.33), and adjusted EBITDA decreased to $(0.4M) from $0.1M.

For Full Year 2024: Operating expenses rose to $88.7M from $88.2M, net loss expanded to $(43.7M) from $(43.2M), loss per share increased to $(1.38) from $(1.37), and adjusted EBITDA declined to $(21.8M) from $(21.3M).